MNOV MediciNova, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

MNOV [NASD]

MediciNova, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.26	Insider Own	0.40%	Shs Outstand	44.09M	Perf Week	1.30%
Market Cap	242.19M	Forward P/E	-	EPS next Y	-0.45	Insider Trans	-0.56%	Shs Float	40.67M	Perf Month	16.49%
Income	-11.50M	PEG	-	EPS next Q	-0.12	Inst Own	21.60%	Short Float	8.33%	Perf Quarter	-50.55%
Sales	-	P/S	-	EPS this Y	16.00%	Inst Trans	0.47%	Short Ratio	1.74	Perf Half Y	-1.81%
Book/sh	1.61	P/B	3.38	EPS next Y	-21.60%	ROA	-14.90%	Target Price	-	Perf Year	-37.90%
Cash/sh	1.36	P/C	4.01	EPS next 5Y	20.00%	ROE	-15.70%	52W Range	2.79 - 13.25	Perf YTD	-19.29%
Dividend	-	P/FCF	-	EPS past 5Y	4.70%	ROI	-	52W High	-58.94%	Beta	1.54
Dividend %	-	Quick Ratio	22.00	Sales past 5Y	-	Gross Margin	-	52W Low	94.98%	ATR	0.26
Employees	8	Current Ratio	22.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	52.80	Volatility	2.93% 3.84%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-12.00%	Profit Margin	-	Rel Volume	0.08	Prev Close	5.41
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.95M	Price	5.44
Recom	1.50	SMA20	2.60%	SMA50	0.11%	SMA200	0.96%	Volume	146,717	Change	0.55%

Mar-25-19

Resumed

B. Riley FBR

Buy

$22

Mar-28-18

Initiated

B. Riley FBR, Inc.

Buy

$22

Apr-18-17

Initiated

Credit Suisse

Outperform

Jan-04-13

Reiterated

Ladenburg Thalmann

Buy

$10.50 → $6

May-24-12

Downgrade

MLV & Co

Buy → Hold

Oct-18-11

Reiterated

MLV Capital

Buy

$13 → $6

Jun-22-11

Initiated

Global Hunter Securities

Buy

May-12-10

Initiated

Wedbush

Outperform

$13

Nov-12-08

Reiterated

Ladenburg Thalmann

Buy

$22 → $6

May-15-08

Initiated

Rodman & Renshaw

Mkt Outperform

Jul-09-07

Initiated

Punk, Ziegel & Co

Buy

$22

Oct-22-20 06:30AM	MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy GlobeNewswire
Oct-21-20 06:30AM	MediciNova Appoints Carolyn Beaver to its Board of Directors and as Audit Committee Chair GlobeNewswire
Oct-13-20 06:30AM	MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience 2020 GlobeNewswire
Sep-24-20 09:24AM	Company News for Sep 24, 2020 Zacks -22.04%
06:30AM	MediciNova Announces Positive Clinical Results Regarding MN-166 (ibudilast) for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and Pharmacology GlobeNewswire
Sep-23-20 10:37AM	MediciNova Stock Spikes on Coronavirus-Vaccine Progress TheStreet.com +8.12%
08:05AM	The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma Benzinga
06:30AM	MediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2 in Mice using BC-PIV Vector Technology GlobeNewswire
Sep-11-20 06:30AM	MediciNova Announces that BioComos Intranasal RS Virus Vaccine Successfully Induced Neutralizing Antibodies against the RS Virus in Mice using BC-PIV Technology GlobeNewswire
Sep-02-20 11:23AM	MNOV: Update on Intranasal SARS-CoV-2 Vaccine Zacks Small Cap Research
Sep-01-20 08:32AM	The Daily Biotech Pulse: Sanofi, Regeneron Drop COVID-19 Study, 2 Positive AstraZeneca Catalysts, Brickell Awarded Japanese Patent Benzinga
06:30AM	MediciNova Announces Development Progress on Intranasal Formulation of SARS-CoV-2 Vaccine for COVID-19 GlobeNewswire
Aug-06-20 06:30AM	MediciNova Announces the Presentation of Positive Results from Phase 2 Trial of MN166 (ibudilast) in Alcohol Use Disorder at the American Psychological Association 2020 Annual Convention GlobeNewswire
Aug-04-20 07:40AM	MNOV: Developing SARS-CoV-2 Vaccine Based on Parainfluenza Virus Vector Zacks Small Cap Research
06:30AM	MediciNova to Participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference GlobeNewswire
Jul-28-20 08:13AM	The Daily Biotech Pulse: Spectrum's Positive Dementia Readout, Pfizer, BioNTech Start Late-Stage Coronavirus Trial, resTORbio Receives COVID-19 Funding Benzinga -32.73%
Jul-27-20 01:09PM	Here's Why MediciNova Is Soaring Today Motley Fool +95.04%
06:30AM	MediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan GlobeNewswire
Jul-20-20 06:30AM	MediciNova to Participate in Panel Discussion at the B. Riley FBR Virtual Infectious Disease Summit GlobeNewswire
Jul-02-20 05:47AM	MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID-19 Patients Zacks Small Cap Research
Jul-01-20 06:30AM	MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) for Prevention of Acute Respiratory Distress Syndrome in Patients with COVID-19 GlobeNewswire +6.83%
Jun-26-20 08:28AM	The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts Benzinga
Jun-25-20 07:00PM	MediciNova Announces Positive Preclinical Results Regarding MN-166 (ibudilast) in Glioblastoma (GBM) Published in Frontiers in Immunology GlobeNewswire
Jun-24-20 08:07AM	The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact Benzinga
Jun-23-20 07:00PM	MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Europe GlobeNewswire
Jun-12-20 12:31PM	Hedge Funds Are Cashing Out Of MediciNova, Inc. (MNOV)? Insider Monkey
May-01-20 11:30AM	MNOV: Multiple Shots on Goal Provide Substantial Potential Upside Zacks Small Cap Research +5.44%
Apr-27-20 10:20AM	Have Insiders Been Buying MediciNova, Inc. (NASDAQ:MNOV) Shares This Year? Simply Wall St.
Apr-20-20 07:00PM	MediciNova Receives Notice of Allowance for Second Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma GlobeNewswire
Apr-14-20 09:20AM	MNOV: MN-166 Trial in ARDS to Initiate at Yale University Zacks Small Cap Research -11.33%
Apr-08-20 07:53AM	The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO Benzinga +37.81%
06:07AM	MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome (ARDS) GlobeNewswire
Mar-12-20 06:40AM	MNOV: MN-166 to be Developed as a Treatment for Severe Pneumonia and Acute Respiratory Distress Syndrome Zacks Small Cap Research
Mar-09-20 07:00PM	MediciNova Announces Plans to Develop MN-166 (ibudilast) for Severe Pneumonia and Acute Respiratory Distress Syndrome (ARDS) GlobeNewswire -6.19%
Feb-27-20 07:23AM	Should You Be Concerned About MediciNova, Inc.'s (NASDAQ:MNOV) Historical Volatility? Simply Wall St. -9.43%
Feb-25-20 08:15AM	MNOV: Multiple Trials of MN-166 Ongoing; Recent Price Move Creates Buying Opportunity Zacks Small Cap Research -6.51%
Feb-17-20 06:00PM	MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Japan GlobeNewswire
Jan-28-20 07:12AM	The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics Benzinga
Jan-27-20 06:00PM	MediciNova Receives Notice of Intention to Grant for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in Europe GlobeNewswire
Dec-04-19 06:00PM	MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th International Symposium on ALS/MND in Perth, Australia GlobeNewswire
Nov-18-19 12:57PM	We're Not Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Simply Wall St.
Nov-06-19 01:50PM	Here is What Hedge Funds Think About MediciNova, Inc. (MNOV) Insider Monkey
Oct-30-19 07:00PM	MNOV: Phase 3 Trial Initiated for MN-166 in ALS Zacks Small Cap Research
Oct-28-19 06:00AM	MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada GlobeNewswire
Oct-23-19 06:00AM	MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of NAFLD and NASH in Japan GlobeNewswire
Oct-07-19 07:00PM	MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Idiopathic Pulmonary Fibrosis in Japan GlobeNewswire
Sep-30-19 07:00PM	MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Idiopathic Pulmonary Fibrosis in China GlobeNewswire
Sep-19-19 03:48PM	Does Market Volatility Impact MediciNova, Inc.'s (NASDAQ:MNOV) Share Price? Simply Wall St.
Sep-11-19 07:00PM	MediciNova to Present at the Ladenburg Thalmann 2019 Healthcare Conference in New York GlobeNewswire
Aug-29-19 07:00PM	MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York GlobeNewswire
Aug-14-19 10:30AM	MNOV: Abstract on MN-166 to be Presented at ALS/MND International Symposium Zacks Small Cap Research
Jul-30-19 07:00PM	MediciNova Announces MN-001 Research Collaboration with the National Cerebral and Cardiovascular Disease Research Center in Japan GlobeNewswire
Jul-29-19 07:00PM	MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 30th International Symposium on ALS/MND in Perth, Australia GlobeNewswire
Jul-24-19 11:00PM	MediciNova Appoints Kazuko Matsuda to its Board of Directors GlobeNewswire
Jul-18-19 04:00PM	MNOV: Readying for Phase 3 Trial in Multiple Sclerosis Zacks Small Cap Research
02:03PM	What Type Of Shareholder Owns MediciNova, Inc.'s (NASDAQ:MNOV)? Simply Wall St.
Jul-11-19 07:00PM	MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS GlobeNewswire
Jun-12-19 07:00PM	MediciNova to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-05-19 07:00PM	MediciNova Announces Kick-off Meeting to Officially Launch Phase 3 Trial of MN 166 (ibudilast) in ALS GlobeNewswire
May-16-19 01:14PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of MediciNova, Inc. GlobeNewswire
May-15-19 07:00PM	MediciNova to Present at the 20th Annual B. Riley FBR Institutional Investor Conference GlobeNewswire
May-09-19 10:00AM	MNOV: Plans in Place for Phase 3 Trial in ALS Zacks Small Cap Research
May-08-19 07:23AM	If You Had Bought MediciNova (NASDAQ:MNOV) Stock Five Years Ago, You Could Pocket A 536% Gain Today Simply Wall St.
May-07-19 07:00PM	MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom GlobeNewswire
Apr-24-19 08:09AM	The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova Benzinga
Apr-23-19 07:00PM	MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma GlobeNewswire +8.15%
Apr-16-19 08:10AM	The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives Benzinga
Apr-15-19 07:00PM	MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS GlobeNewswire
Apr-08-19 09:45AM	MNOV: New Analysis Shows Efficacy of MN-166 in Non-Relapsing SPMS Zacks Small Cap Research
Apr-03-19 07:00PM	MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in China GlobeNewswire
Apr-01-19 07:00PM	MediciNova Announces Results of Subgroup Analysis from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS GlobeNewswire
Mar-24-19 07:00PM	MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in Philadelphia, Pennsylvania GlobeNewswire
Mar-05-19 06:51PM	MediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan GlobeNewswire
Feb-28-19 06:00PM	MediciNova Announces the Publication of Results of the Animal Model Study of MN166 (ibudilast) in Glioblastoma in Scientific Reports GlobeNewswire
Feb-20-19 10:00AM	MNOV: Continuing to Plan for Phase 3 Studies in Progressive MS and ALS Zacks Small Cap Research
Feb-12-19 01:30PM	One Thing To Remember About The MediciNova, Inc. (NASDAQ:MNOV) Share Price Simply Wall St.
Jan-21-19 06:00PM	MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative Diseases GlobeNewswire
Jan-09-19 07:39AM	The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study Benzinga
Jan-08-19 06:00PM	MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma GlobeNewswire +9.13%
Jan-07-19 06:00PM	MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan GlobeNewswire
Dec-12-18 10:06AM	Do Insiders Own Lots Of Shares In MediciNova, Inc. (NASDAQ:MNOV)? Simply Wall St. +6.69%
06:00AM	MediciNova to Present at the J.P. Morgan Healthcare Conference in San Francisco GlobeNewswire
Oct-31-18 10:00AM	MNOV: MN-166 to be Studied in Degenerative Cervical Myelopathy Zacks Small Cap Research +5.29%
Oct-05-18 08:35AM	The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker Benzinga
Oct-04-18 07:00PM	MediciNova Announces FDA Grants Orphan Drug Designation to MN-166 (ibudilast) for Glioblastoma GlobeNewswire
Sep-28-18 09:45AM	MNOV: Positive FDA Feedback on ALS Phase 3 Plan Zacks Small Cap Research
Sep-25-18 07:00PM	MediciNova Announces Positive FDA Feedback Regarding Phase 3 Plan for MN-166 (ibudilast) in ALS GlobeNewswire
Sep-18-18 07:00PM	MediciNova to Present at the Ladenburg Thalmann 2018 Healthcare Conference in New York GlobeNewswire
Sep-04-18 07:00PM	MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York GlobeNewswire
Aug-29-18 05:00PM	MediciNova Announces the Publication of Results of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS in the New England Journal of Medicine GlobeNewswire +5.40%
Aug-20-18 07:00PM	National Institute on Alcohol Abuse and Alcoholism Awards R01 Research Grant to UCLA for Phase 2b Clinical Trial of MediciNova's MN-166 (ibudilast) in Alcohol Use Disorder GlobeNewswire
07:50AM	Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Aug-06-18 07:00PM	MediciNova Announces Initiation of NIHR Grant-Funded Phase 2/3 Trial of MN-166 (ibudilast) for the Treatment of Degenerative Cervical Myelopathy in Collaboration with the University of Cambridge GlobeNewswire
Jul-31-18 07:00PM	MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 29th International Symposium on ALS/MND in Glasgow, Scotland, UK GlobeNewswire
Jul-29-18 07:00PM	MediciNova Announces Full Enrollment in ALS Biomarker Clinical Trial GlobeNewswire
Jul-25-18 09:15AM	MNOV: Plenty of Cash to Advance Pipeline Forward Zacks Small Cap Research
Jul-12-18 09:30AM	MNOV: Encouraging Data from Subgroup Analysis of ALS Study Zacks Small Cap Research
Jul-09-18 07:00PM	MediciNova Announces Clinical Data from Subgroup Analyses of Completed Clinical Trial of MN-166 (ibudilast) in ALS GlobeNewswire
Jun-19-18 07:00PM	MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia and Hypercholesterolemia in Japan GlobeNewswire
Jun-05-18 07:35AM	Detailed Research: Economic Perspectives on Galapagos NV, Cellectis S.A, MediciNova, Logitech International S.A, The Descartes Systems Group, and Canadian Pacific Railway What Drives Growth in Today's Competitive Landscape GlobeNewswire

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nagao Hideki	Director	Sep 15	Sale	5.78	1,000	5,780	15,000	Sep 16 04:32 PM
Nagao Hideki	Director	Aug 06	Option Exercise	2.58	15,000	38,700	16,000	Aug 07 08:53 PM
Matsuda Kazuko	Chief Medical Officer	Jun 12	Option Exercise	5.13	20,000	102,600	160,192	Jun 15 05:02 PM
Matsuda Kazuko	Chief Medical Officer	Apr 08	Option Exercise	2.54	28,446	72,253	140,192	Apr 13 09:42 PM
IWAKI YUICHI	President and CEO	Apr 08	Option Exercise	2.54	60,417	153,459	841,100	Apr 13 09:40 PM
Matsuda Kazuko	Chief Medical Officer	Mar 13	Buy	3.62	2,000	7,240	111,476	Mar 13 05:53 PM
IWAKI YUICHI	President and CEO	Mar 12	Buy	3.10	20,000	62,000	780,683	Mar 12 06:39 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience